Drug interactions
Brentuximab + Larotrectinib
Severity: Minor
Brentuximab and Larotrectinib: minor interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Larotrectinib is a weak CYP3A4 inhibitor and could slightly increase MMAE exposure from brentuximab vedotin. A meaningful clinical effect is unlikely.
What this interaction means in plain words
Brentuximab and Larotrectinib have a small, usually unimportant interaction. Most people can take both; the pharmacist may still mention it so that any unexpected effect is recognised.
Brentuximab belongs to Oncology; Larotrectinib belongs to Oncology.
Why it happens
Weak CYP3A4 inhibition reduces MMAE metabolism.
What to do
No dose adjustment needed; monitor for neutropenia and neuropathy.
What to ask your pharmacist
- Is there anything I should notice while taking both?
- Do I need to tell my doctor at the next visit?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Brentuximab and Larotrectinib, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 7 days on the web. No card needed.
Other interactions of Brentuximab
- Bleomycin + Brentuximab Contraindicated
- Brentuximab + Dengue vaccine Major
- Brentuximab + Etrasimod Major
- Brentuximab + Idelalisib Major
- Brentuximab + Levoketoconazole Major
- Brentuximab + Nefazodone Major
Other interactions of Larotrectinib
Frequently asked questions
Can I take Brentuximab with Larotrectinib?
MediHelp rates the interaction as minor. Brentuximab and Larotrectinib have a small, usually unimportant interaction. Most people can take both; the pharmacist may still mention it so that any unexpected effect is recognised. Larotrectinib is a weak CYP3A4 inhibitor and could slightly increase MMAE exposure from brentuximab vedotin. A meaningful clinical effect is unlikely.
How serious is the interaction between Brentuximab and Larotrectinib?
MediHelp rates it minor, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: No dose adjustment needed; monitor for neutropenia and neuropathy.
What other medicines interact with Brentuximab?
MediHelp also lists interactions of Brentuximab with, for example, Bleomycin, Dengue vaccine, Etrasimod. The full list is on the Brentuximab page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
